F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).
about
To Revascularise or Not To Revascularise, That Is the Question: the Diagnostic and Management Conundrum of Ischaemic CardiomyopathyClinical decision making with myocardial perfusion imaging in patients with known or suspected coronary artery diseaseAppropriateness criteria for cardiovascular imaging use in heart failure: report of literature reviewImaging myocardial metabolic remodeling.Impact of preoperative positron emission tomography in patients with severely impaired LV-function undergoing surgical revascularization.PET-CMR in heart failure - synergistic or redundant imaging?Should Chronic Total Occlusion Be Treated With Coronary Artery Bypass Grafting? Chronic Total Occlusion Should Not Routinely Be Treated With Coronary Artery Bypass GraftingMolecular and cellular basis of viable dysfunctional myocardium.Diagnostic value of (18)F-FDG PET in the assessment of myocardial viability in coronary artery disease: A comparative study with (99m)Tc SPECT and echocardiography.Prediction of long-term segmental and global functional recovery of hibernating myocardium after revascularisation based on low dose dobutamine and late gadolinium enhancement cardiovascular magnetic resonance.Noninvasive assessment myocardial viability: current status and future directions.Radionuclide Imaging of Viable Myocardium: Is it Underutilized?Myocardial viability and survival in ischemic left ventricular dysfunction.Viability assessment after conventional coronary angiography using a novel cardiovascular interventional therapeutic CT system: Comparison with gross morphology in a subacute infarct swine model.Coronary-artery bypass surgery in patients with left ventricular dysfunctionSeverity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization.Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH.Myocardial perfusion scintigraphy: past, present and futureAlternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial.Pathophysiology of coronary artery disease: the case for multiparametric imaging.Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit?: Myocardial imaging should not exclude patients with ischemic heart failure fromCost-effectiveness of initial stress cardiovascular MR, stress SPECT or stress echocardiography as a gate-keeper test, compared with upfront invasive coronary angiography in the investigation and management of patients with stable chest pain: mid-teImpaired coronary flow reserve is the most important marker of viable myocardium in the myocardial segment-based analysis of dual-isotope gated myocardial perfusion single-photon emission computed tomography.Myocardial viability imaging and revascularization in chronic ischemic left ventricular systolic dysfunction.Heart failure in the elderly: advances and challenges.PET and PET/CT in cardiovascular disease.Evaluation of myocardial ischemia and viability by noninvasive cardiac imaging.Multimodality imaging for assessment of myocardial viability: nuclear, echocardiography, MR, and CT.Prognosis in the era of comparative effectiveness research: where is nuclear cardiology now and where should it be?Assessing the available techniques for testing myocardial viability: what does the future hold?The hibernating myocardium: current concepts, diagnostic dilemmas, and clinical challenges in the post-STICH era.Is ischemia the most powerful indicator of myocardial viability?Revascularization in heart failure in the post-STICH era.Assessing the prognostic implications of myocardial perfusion studies: identification of patients at risk vs patients who may benefit from intervention?New insights from major prospective cohort studies with cardiac nuclear imaging.The benefits of revascularization in chronic heart failure.Proceedings of the ASNC Cardiac PET Summit, 12 May 2014, Baltimore, MD : 1: The value of PET: Integrating cardiovascular PET into the care continuum.Revascularization in Severe Left Ventricular Dysfunction: Does Myocardial Viability Even Matter?Ischaemic cardiomyopathy: pathophysiology, assessment and the role of revascularisation.Radionuclide Imaging Applications in Cardiomyopathies and Heart Failure.
P2860
Q26749674-444EF037-77EC-4696-8ACD-F0B19408BD31Q26859183-27588ADE-707D-42CF-ADF6-CBE8964A0FE2Q26992237-492F8F5F-3F8C-4EA8-91D2-0DD724F2838DQ30464469-5FB9458E-7F61-45B5-9079-7FC783CC5F21Q33781237-4282E60D-5CB2-432D-BECD-69E9D2A6C22AQ33844251-EACC5CD8-3F7C-4640-AB99-26EAA9943D9AQ33894096-BD59EA82-5BD9-450B-8A87-81672C8B8C9CQ33924001-E24DAF33-B120-4768-A4C0-CF2D33D1E36AQ34260453-BBE01346-C466-47BD-86B4-94AF574F5F90Q34304041-9DDD8E09-85B4-47BF-8A65-A4FFE5BD2FAAQ34774619-10836DEB-CDD2-4C2F-972A-DF83E81BC347Q34892889-0CC09999-9BD7-472F-850B-D1785BE5C956Q35791994-F51F4C7E-900E-4213-BC47-FAE009CC7A8CQ36081641-8DEE0CD6-CF4C-4F08-A192-E111CDF2D184Q36152222-F3A05F55-1AC3-49D2-A5FF-DE0FB5AD01CEQ36248209-902DD0D0-1192-4621-AFF1-97A06B044695Q36306239-5C7797F5-2A85-48ED-9CC6-08F3DA084100Q36325479-945EC06F-2EB4-4CA8-A260-F8E5E26A3899Q37060322-93AD9C98-10C2-4D13-B991-A4E00712F69BQ37417701-3941D281-6EAD-4EC0-9B49-CC2959B2D621Q37427428-9CE0CDCB-E7A6-4305-B083-6C45DA892DECQ37572029-8BA8FE0B-DEBC-48BF-B1F3-CA47A842A19AQ37640164-9CA0E6FD-1837-405C-8677-EECC5E7894CFQ37656286-F5E40D60-A3FF-4D75-A6EB-ED8D8D28971AQ37744960-728D2D43-DF8B-4983-9698-F5161DC7EF76Q37896144-C380472E-6408-4B39-B747-6B277057AD28Q37965658-CC3F0A91-5F93-460F-8243-8943C1443567Q37974592-D04B5478-CBEC-4724-8E80-3ACC732E6B25Q38023739-218B2486-B78F-4E61-A1A9-96F099A8BCE5Q38062030-50A8DFDA-CBAF-4773-97CF-AAF60B29EF37Q38082761-3C187F8A-4BE6-4DB9-BC5D-6171FEAF2508Q38091374-A6973A65-3327-4BC9-8193-7EDFA3FA97F5Q38154221-1281FC67-E9E2-415F-A255-7A52505E59E2Q38192519-CF70C5EC-29B4-4170-A2D2-EB8FAF11D0A6Q38197125-74A84099-F501-468D-9BC7-B7474A3BDBA4Q38286993-0A81565A-F91D-420A-88AF-303C7A0E9283Q38439405-542B0955-7910-4492-8455-78639E4EEF9CQ38544269-B60F5458-71DC-4A17-BA67-B13C35AF15F8Q38689158-30082BCA-9C3D-4DF6-B5C0-BF0D4E5C4458Q38721841-BE96A4D8-F940-4580-8D31-58B50E722647
P2860
F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
F-18-fluorodeoxyglucose positr ...... ed, controlled trial (PARR-2).
@en
F-18-fluorodeoxyglucose positr ...... ed, controlled trial (PARR-2).
@nl
type
label
F-18-fluorodeoxyglucose positr ...... ed, controlled trial (PARR-2).
@en
F-18-fluorodeoxyglucose positr ...... ed, controlled trial (PARR-2).
@nl
prefLabel
F-18-fluorodeoxyglucose positr ...... ed, controlled trial (PARR-2).
@en
F-18-fluorodeoxyglucose positr ...... ed, controlled trial (PARR-2).
@nl
P2093
P1476
F-18-fluorodeoxyglucose positr ...... zed, controlled trial (PARR-2)
@en
P2093
André Lamy
Dennis Humen
Ella Huszti
Graham Nichol
Karen Y Gulenchyn
Linda Garrard
Michael Freeman
Normand Racine
PARR-2 Investigators
P304
P356
10.1016/J.JACC.2007.09.006
P407
P577
2007-10-10T00:00:00Z